COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?-Reference-Cited by-同舟云学术

COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Published:2020-08-07 Issue:10 Volume:26 Page:1267-1267
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Brownlee Wallace J¹

Affiliation:

1. Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, London, UK/National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458520948211

Reference6 articles.

1. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

2. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment

3. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

4. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies

5. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study;Multiple Sclerosis and Related Disorders;2021-10

2. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic;Biomolecules;2021-09-17

3. Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD;BMC Neurology;2021-05-01

4. Response of the multiple sclerosis community to COVID-19;Multiple Sclerosis Journal;2020-09